Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response

被引：0
|
作者：
Saad, F [1 ]
机构：
[1] CHU Montreal, Hop Notre Dame de Bon Secours, Urooncol Clin, Montreal, PQ H2L 4M1, Canada
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2003年 / 95卷 / 15期
关键词：
D O I：
10.1093/jnci/djg021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：1175 / 1175
页数：1
相关论文
共 50 条
  • [1] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response
    Saad, F
    Gleason, DM
    Murray, R
    Goas, JA
    Chen, B
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (04) : 333 - 334
  • [2] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response
    Saad, F
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) : 1183 - 1184
  • [3] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Winquist, E
    Berry, S
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1183 - 1183
  • [4] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Atkins, CD
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (04) : 332 - 332
  • [5] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Tu, SM
    Lin, SH
    Logothetis, C
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (15) : 1174 - 1175
  • [6] A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Saad, F
    Gleason, DM
    Murray, R
    Tchekmedyian, S
    Venner, P
    Lacombe, L
    Chin, JL
    Vinholes, JJ
    Goas, JA
    Chen, B
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19): : 1458 - 1468
  • [7] Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer
    Vordos, D
    Paule, B
    Vacherot, F
    Allory, Y
    Salomon, L
    Hoznek, A
    Yiou, R
    Chopin, D
    Abbou, CC
    de la Taille, A
    BJU INTERNATIONAL, 2004, 94 (04) : 524 - 527
  • [8] A controlled prospective randomized placebo-controlled trial of Zoledronic acid in bony metastatic bladder cancer patients
    Zaghloul, M. S.
    Boutrus, R.
    El-Hosieny, H.
    A-Kader, Y.
    El-Attar, I.
    Nazmy, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer - Response
    Saad, F
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) : 70 - 71
  • [10] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer - Response
    Saad, F
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19): : 1480 - 1481
12345